checkAd
    Startseite > Aktien > Castle Biosciences > Nachrichten
    Castle Biosciences Aktie
    19,860
     
    USD
    -1,00 %
    -0,200 USD
    Letzter Kurs 02:00:00 Nasdaq
    19,830
     
    USD
    800 STK
    Geldkurs 24.04.24
    19,910
     
    USD
    400 STK
    Briefkurs 24.04.24
    ISIN: US14843C1053 · WKN: A2PNH3 · SYM: CSTL · USA

    Neueste Nachrichten

    Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
    11.04.24 · Business Wire (engl.) · Castle Biosciences
    Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
    10.04.24 · Business Wire (engl.) · Castle Biosciences
    Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
    10.04.24 · Business Wire (engl.) · Castle Biosciences
    Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer
    04.04.24 · Business Wire (engl.) · Castle Biosciences
    Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
    02.04.24 · Business Wire (engl.) · Castle Biosciences
    Castle Biosciences Announces Updates to its Board of Directors
    27.03.24 · Business Wire (engl.) · Castle Biosciences
    Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
    25.03.24 · Business Wire (engl.) · Castle Biosciences
    Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
    22.03.24 · Business Wire (engl.) · Castle Biosciences
    Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
    19.03.24 · Business Wire (engl.) · Castle Biosciences
    New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
    15.03.24 · Business Wire (engl.) · Castle Biosciences
    Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
    12.03.24 · Business Wire (engl.) · Castle Biosciences
    Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
    08.03.24 · Business Wire (engl.) · Castle Biosciences